Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00284817
Recruitment Status : Completed
First Posted : February 1, 2006
Last Update Posted : May 29, 2008
Sponsor:
Information provided by:
MedImmune LLC

Tracking Information
First Submitted Date  ICMJE January 31, 2006
First Posted Date  ICMJE February 1, 2006
Last Update Posted Date May 29, 2008
Study Start Date  ICMJE July 2001
Actual Primary Completion Date January 2005   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 27, 2008)
The recommended Phase II dose will be based on acceptable dose-limiting toxicity [ Time Frame: Study Days 0, 7, 14, 21, 28, 35, 42, and 49. ]
Original Primary Outcome Measures  ICMJE
 (submitted: January 31, 2006)
The recommended Phase II dose will be based on acceptable dose-limiting toxicity
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 27, 2008)
Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response [ Time Frame: Study Days 0, 28, 56, 84, 112, 140, 168, 196, 224, 252, 280, 308, 336, 357; and tumor response on Study Days 56, 112, 168, 224, 280, 336, and 387. ]
Original Secondary Outcome Measures  ICMJE
 (submitted: January 31, 2006)
Pharmacokinetic parameters may also be factored into the determination of a Phase II dose.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Official Title  ICMJE Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer or Other Solid Tumors Refractory to Standard Therapy
Brief Summary - Assess the safety and tolerance of a weekly MEDI522 regimen in patients with irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.
Detailed Description
  • Assess the safety and tolerance of a weekly MEDI 522 regimen in patients with irinotecan-refractory advanced CRC.
  • Determine a Phase II recommended dose based on acceptable dose-limiting toxicity. Other considerations such as pharmacokinetic parameters may also be factored into the determination of a Phase II dose.

The secondary objectives of the study are to:

  • Assess any antitumor activity of MEDI-522 in this patient population.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cancer
Intervention  ICMJE
  • Drug: MEDI-522
    Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
  • Drug: MEDI-522
    Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
  • Drug: MEDI-522
    Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
  • Drug: MEDI-522
    Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
  • Drug: MEDI-522
    The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
Study Arms  ICMJE
  • Experimental: 1
    MEDI-522
    Intervention: Drug: MEDI-522
  • Experimental: 2
    MEDI-522
    Intervention: Drug: MEDI-522
  • Experimental: 3
    MEDI-522
    Intervention: Drug: MEDI-522
  • Experimental: 4
    MEDI-522
    Intervention: Drug: MEDI-522
  • Experimental: 5
    MEDI-522
    Intervention: Drug: MEDI-522
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 27, 2008)
17
Original Enrollment  ICMJE
 (submitted: January 31, 2006)
20
Actual Study Completion Date  ICMJE May 2005
Actual Primary Completion Date January 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have histologically-confirmed advanced CRC that has progressed through an irinotecan-containing regimen for metastatic disease, or has recurred during, or within 6 months of completing, an irinotecan-containing adjuvant regimen, or other histologically-confirmed solid tumors refractory to standard therapy.
  • Age at least 18 years at the time of the first dose of study drug.
  • Both males and females are eligible. Sexually active females, unless surgically sterile (or at least one year post-menopausal), must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug, and must agree to continue using such precautions for 30 days after the final dose of study drug. Sexually active females of reproductive potential must have a negative serum b human chorionic gonadotropin (bhCG) pregnancy test within 3 days of start of therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. ECOG criteria are described in Appendix A.
  • Patients who had prior treatment with chemotherapy or radiotherapy or had prior surgery are eligible for study entry if at least 4 weeks have past since their treatment/surgery.
  • All toxicities related to prior treatment must have resolved and all surgical wounds must have healed.
  • Prior immunotherapy with approved agents is allowable.
  • ANC ³1500/mm3, platelets ³100,000/mm3, hemoglobin >10.0 g/dL, serum creatinine £1.5 mg/dL or calculated creatinine clearance >50 mL/min, serum bilirubin £2.0 mg/dL, and AST/ALT £5 times the upper limit of normal (ULN).
  • PT/PTT less than ULN or international normalized ratio (INR) less than 1.12.
  • Thyroxine (T4) and thyroid-stimulating hormone (TSH) within normal limits.
  • Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures.

Exclusion Criteria:

  • Pregnancy or nursing.
  • Known brain metastases or primary brain tumors, symptomatic pleural effusion or ascites requiring paracentesis.
  • Respiratory insufficiency requiring oxygen treatment, or lymphangitic involvement of lungs.
  • Any evidence of hematemesis, melena, hematochezia, or gross hematuria.
  • A history of significant adverse events related to a previously administered humanized monoclonal antibody.
  • A known human immunodeficiency virus (HIV) or hepatitis virus infection.
  • A prior myocardial infarction or angina, or uncontrolled hypertension (systolic blood pressure >150 mm Hg).
  • A prior stroke or transient ischemic attack.
  • An active infection requiring systemic antiinfective therapy.
  • Received an investigational agent in the last 4 weeks of initiation of study treatment.
  • A requirement for palliative chemotherapy, hormonal therapy, or immunotherapy during the course of the study.
  • Clinical evidence of bowel obstruction.
  • A history of other malignancies within the past 5 years (with the exception of basal cell carcinoma of the skin or completely excised in situ carcinoma of the cervix).
  • A general medical or psychological condition or behavior, including substance dependence or abuse that, in the opinion of the investigator, might not permit the patient to complete the study or sign the informed consent.
  • Prior treatment with MEDI-522 or MEDI-523.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00284817
Other Study ID Numbers  ICMJE MI-CP068
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Luz Hammershaimb, M.D., V.P., Clinical Dev., MedImmune LLC
Study Sponsor  ICMJE MedImmune LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Krista Arbaugh, Dir., Clinical Ops MedImmune LLC
PRS Account MedImmune LLC
Verification Date May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP